Research article · 26 Jul 2022
EditorialPublished 20 Feb 2017
EGFR - An Evolving Cancer Target
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The Epidermal Growth Factor Receptor (EGFR) plays an important role in initiating the signaling that directs the behaviour of epithelial cells and tumors of epithelial origin. EGFR is involved in cell signaling that controls cell proliferation, survival, and metastasis by regulating diverse cellular pathways, and is the most frequently mutated receptor in lung cancer (10% in the USA, 35% in Asia) [1,2], prompting an intensive effort to develop an effective drug to overcome EGFR-mutant-driven cancers. Resistance to EGFR tyrosine kinase inhibitors occurs in many cases of lung cancer. Here, we present a concise overview of the mechanisms involved in resistance and discusses a new approach to overcoming them.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.
More from this journal
The newest in Cancer Biology and Therapeutic Oncology.
Review article · 28 Jun 2022
Meddling of Viral Genome can Contribute Cancer by Cumulating the Global Burden
Conference abstract · 27 Mar 2022
Research progress of YTH domain protein family
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Biology and Therapeutic Oncology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Dakir EL-H”
- BylineArticles whose byline prints “Tanani EL-M”
- BylineArticles whose byline prints “Dakir NM”
- BylineArticles whose byline prints “Mendoza A”
- BylineArticles whose byline prints “Morgan R”
